Revance Therapeutics, Inc.
RVNC · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $743,629 | $1,342,288 | $1,101,728 | $1,643,980 |
| - Cash | $137,329 | $108,965 | $110,623 | $333,558 |
| + Debt | $478,434 | $418,468 | $324,512 | $212,109 |
| Enterprise Value | $1,084,734 | $1,651,791 | $1,315,617 | $1,522,531 |
| Revenue | $234,040 | $132,565 | $77,798 | $15,325 |
| % Growth | 76.5% | 70.4% | 407.7% | – |
| Gross Profit | $81,877 | $80,898 | $54,388 | $10,556 |
| % Margin | 35% | 61% | 69.9% | 68.9% |
| EBITDA | -$290,637 | -$305,516 | -$255,184 | -$259,310 |
| % Margin | -124.2% | -230.5% | -328% | -1,692.1% |
| Net Income | -$323,986 | -$356,422 | -$286,824 | -$282,089 |
| % Margin | -138.4% | -268.9% | -368.7% | -1,840.7% |
| EPS Diluted | -3.83 | -4.9 | -4.25 | -4.86 |
| % Growth | 21.8% | -15.3% | 12.6% | – |
| Operating Cash Flow | -$216,575 | -$193,548 | -$221,538 | -$178,502 |
| Capital Expenditures | -$6,886 | -$23,010 | -$18,075 | -$4,216 |
| Free Cash Flow | -$223,461 | -$216,558 | -$239,613 | -$182,718 |